hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06309823 id: 1000080330 briefTitle: A Single-patient Clinical Trial of MAS825 in a Patient With XIAP Deficiency overallStatus: COMPLETED date: 2023-02-08 date: 2024-01-17 date: 2024-01-17 date: 2024-03-13 date: 2024-03-13 name: The Hospital for Sick Children class: OTHER briefSummary: MAS825 is a bi-specific IgG1 monoclonal antibody that simultaneously targets IL-1 beta and IL-18, thereby neutralizing both cytokines that are thought to be integral to the pathogenesis of XLP-2. Clinical trials are currently examining its efficacy in other diseases associated with elevations of these cytokines, including NLRC4-associated disease and hidradenitis suppurativa. This study proposes to assess the effectiveness of MAS825 in a single patient with XLP-2, who has previously demonstrated response to blockade of IL-1 beta and IL-18. Given the lack of alternative pharmaceutical options for XLP-2, this represents the only known medication option that avoids the toxicity associated with high-dose corticosteroids and the morbidity associated with hematopoietic stem cell transplantation. conditions: X-linked Lymphoproliferative Syndrome Type 2 (XLP-2) studyType: INTERVENTIONAL phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 1 type: ACTUAL name: MAS825 measure: Impact of MAS825 on Physician Global Assessment Score measure: Impact of MAS825 on Physician Severity Assessment of Disease Signs and Symptoms measure: Patient/Parent Global Assessment of Disease Activity sex: MALE minimumAge: 13 Years maximumAge: 14 Years stdAges: CHILD facility: The Hospital for Sick Children city: Toronto state: Ontario zip: M5G1X8 country: Canada lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06309810 id: 2022-35 briefTitle: Stereotactic Radiosurgery (SRS) in Malignant Spasticity and Hypertonia overallStatus: RECRUITING date: 2023-03-06 date: 2025-08 date: 2025-08 date: 2024-03-13 date: 2024-03-13 name: IRCCS Sacro Cuore Don Calabria di Negrar class: OTHER briefSummary: This is a pilot, experimental, monocentric study. The main objective of the study is to evaluate whether stereotactic radiotherapy is able to reduce symptomatic spasticity from a clinical point of view, and therefore induce an improvement in posture and quality of life in patients with malignant spasticity.
The study foresees the enrollment of about 10 patients, in a period of 24 months. The radiotherapy treatment will be delivered in a single session with an image-guided stereotaxic technique, and a prescription dose between 45 and 60 Gy; subsequently the patients will be followed up for one year. conditions: Spasticity/Paresis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Radiotherapy measure: MAS measure: Acute and late toxicity (CTCAE) measure: Quality of life (SF-12) measure: Quality of nursing (VAS) measure: Radiological characteristics and treatment-related changes of the spinal roots sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Sacro Cuore Don Calabria di Negrar status: RECRUITING city: Negrar state: Verona zip: 37024 country: Italy name: Luca Nicosia, Doctor role: CONTACT phone: +39(0)456014800 email: luca.nicosia@sacrocuore.it lat: 45.52918 lon: 10.93899 hasResults: False
nctId: NCT06309797 id: OSATAGUN2 briefTitle: Effects of Interdental Brush Dipped in 0.2% Hyaluronic Acid Gel on Periodontitis overallStatus: COMPLETED date: 2023-05-02 date: 2024-01-26 date: 2024-02-05 date: 2024-03-13 date: 2024-03-13 name: Özlem SARAÇ ATAGÜN class: OTHER briefSummary: This study aimed to compare the effects of using an interdental brush dipped in 0.2% HA gel with those of using a regular interdental brush on clinical periodontal parameters following SRP among patients with periodontitis. conditions: Periodontitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: single-center, single-blinded, randomized controlled trial primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The investigator carrying out the measurements was not aware of which patients were assigned to the test group. whoMasked: INVESTIGATOR count: 60 type: ACTUAL name: Interdental brush+HA name: Interdental brush measure: Gingival index (GI) measure: Plaque index (PI) measure: Papillary bleeding index (PBI) measure: Pocket depth (PD) measure: Clinical attachment loss (CAL) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sağlık Bilimleri Üniversitesi Gülhane Diş Hekimliği Fakültesi city: Ankara zip: 06010 country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06309784 id: RD 2595 id: NIHR II-LA-1116-20004 type: OTHER_GRANT domain: NIHR briefTitle: Development of a Drill Guidance System to Aid Intra-operative Surgical Drilling overallStatus: RECRUITING date: 2024-03-19 date: 2024-07-31 date: 2024-10-31 date: 2024-03-13 date: 2024-04-10 name: Royal United Hospitals Bath NHS Foundation Trust class: OTHER name: University of Bath name: Great Western Hospitals NHS Foundation Trust briefSummary: The Investigators have developed a camera based drill guidance system to improve the accuracy of surgical drilling. The aim of the study is to assess:
Accuracy in vivo Safety Acceptability of use amongst surgeons and theatre staff conditions: Orthopaedic Surgery studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Participants undergoing orthopaedic Surgery primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Drill Guidance System (DGS) measure: Accuracy of placement of a screw or K wire in scaphoid bones measure: Accuracy of placement of a screw or K wire in other bones measure: Length of material part of the procedure measure: Number of fluoroscopy (perioperative X-ray) images performed measure: Number of patients with treatment related adverse events as assessed by CTCAE v4.0 measure: Immediate acceptability to surgeons and theatre staff measure: Initial acceptability to surgeons and theatre staff measure: Overall acceptability to surgeons and theatre staff sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Royal United hospitals NHS Foundation Trust status: RECRUITING city: Bath country: United Kingdom name: Jane Carter, BSc role: CONTACT phone: 01225821095 email: jane.carter14@nhs.net lat: 51.3751 lon: -2.36172 facility: Great Western Hospital MHS foundation Trust status: RECRUITING city: Swindon country: United Kingdom name: Adam Smith, FRCS role: CONTACT phone: 07533793889 email: adam.smith@doctors.org.uk lat: 51.55797 lon: -1.78116 hasResults: False
nctId: NCT06309771 id: PROMESS - QOL briefTitle: Preventive Remediation for Optimal MEdical StudentS (PROMESS) acronym: PROMESS overallStatus: ENROLLING_BY_INVITATION date: 2023-11-11 date: 2024-09-30 date: 2024-09-30 date: 2024-03-13 date: 2024-03-13 name: Research on Healthcare Performance Lab U1290 class: OTHER briefSummary: Medical students are under a great deal of competitive pressure throughout their training. During their studies, medical students experience high levels of stress, sleep disorders and excessive physical inactivity. These feelings and behaviours are expected to significantly degrade their quality of life, health and performance.
nctId: NCT06309758 id: 115022 briefTitle: BreinZorg: Feasibility Study Into an Online Lifestyle Platform for MCI and SCD overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-04-15 date: 2025-04-15 date: 2024-03-13 date: 2024-04-10 name: Radboud University Medical Center class: OTHER briefSummary: Dementia is the most common disease in older individuals and this century's biggest healthcare challenge. Many patients who visit the memory clinic with memory complaints do not have dementia but instead are diagnosed with mild cognitive impairment (MCI) or subjective cognitive decline (SCD). MCI or SCD may be a pre-dementia stage. Many patients with MCI or SCD often leave their consultation with unanswered questions, and unsure what they, themselves can do to reduce dementia risk. Patients with MCI and SCD have a heightened risk of developing dementia. Therefore, this group would possibly benefit most from preventive strategies. Around 40% of dementia cases is attributable to modifiable factors. Thus, managing a healthy lifestyle may reduce dementia risk.
Participants will have access to the website and are free to use the website in any way they want. conditions: Mild Cognitive Impairment conditions: Cognitive Decline studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: mixed-method study with a single-arm pre-post design with a duration of 3 months and extended follow-up after 6 months. primaryPurpose: PREVENTION masking: NONE count: 60 type: ESTIMATED name: Breinzorg measure: Acceptability of the new online website following the theoretical framework of acceptability measure: Adoption / Uptake of the new online website. Website usage data. measure: Demand of the new online website. Website usage data. measure: Practicality of the new online website. measure: Feeling of trust in yourself and your own abilities. measure: Feeling of control about own life and future. measure: Motivation to change lifestyle for reduction of dementia risk. measure: Awareness about dementia risk reduction measure: Change in alcohol consumption measure: Change in smoking behaviour measure: Change in physical exercise. measure: Change in Diet. measure: Change in Sleep behaviour measure: Change in cognitive activities. measure: Change in Stress levels measure: Change in Mental health Quality of Life sex: ALL minimumAge: 61 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06309745 id: THERATEST briefTitle: THERApy De-escalation for TESTicular Cancer acronym: THERATEST overallStatus: RECRUITING date: 2024-01-25 date: 2027-05 date: 2027-12 date: 2024-03-13 date: 2024-03-13 name: Queen Mary University of London class: OTHER briefSummary: THERATEST is looking to collect data from 30 patients actively receiving de-escalation treatments or other standard of care treatments in two UK hospitals. THERATEST is a feasibility study to determine whether patients are willing to be recruited, the impact of de-escalation treatments on patients' cancers and quality of life, whether we should proceed with these treatments in a larger study, and if so how the study should be conducted. A feasibility study prepares the ground for a larger study and improves the chances of the subsequent study producing valuable evidence, and helps to avoid wasting precious resources on larger trials that are unlikely to be informative. We hope that information from THERATEST will bridge the current knowledge gap and allow clinicians to design bigger trials to actively compare the different treatment strategies. conditions: Seminoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: retroperitoneal lymph node dissection name: Carboplatin AUC10 measure: FEASIBILITY of recruitment and retention measure: QUALITY OF LIFE assessed by difference in HRQOL scores measure: QUALITY OF LIFE assessed by difference in differences in sexual drive, function, and overall satisfaction measure: Progression free SURVIVAL measure: OVERALL SURVIVAL measure: SAFETY and complication of all treatments sex: MALE minimumAge: 16 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Barts and London Hospital NHS Trust status: RECRUITING city: London country: United Kingdom name: THERATEST Study coordinator role: CONTACT lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06309732 id: 4491 id: 2006-001963-52 type: EUDRACT_NUMBER id: TE 2006-09 type: OTHER domain: Barts and the London NHS Trust briefTitle: GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT) acronym: GAMEC-II overallStatus: COMPLETED date: 2006-07 date: 2013-06 date: 2014-01 date: 2024-03-13 date: 2024-03-13 name: Queen Mary University of London class: OTHER briefSummary: St Bartholomew's hospital completed a study using the regimen GAMEC (PEG-filgrastim, actinomycin-D, methotrexate, etoposide, cisplatin). The results of this study showed that 50% of patients with relapsed testicular cancer could be cured using this treatment. These results are very encouraging and compare very favourably to other treatment protocols. In reviewing this study, it became clear that of the 5 cycles of treatment which were proposed, the first 3 seemed to matter and the last 2 did not appear important. In addition there was a group of patients who appeared to do particularly well namely patients under the age of 35 and those who had a normal LDH (lactate dehydrogenase). LDH is a blood test which monitors cancer activity. Selecting patients which fill both these criteria, this trial aims to see whether the investigators can maintain the good results the investigators have seen but using only 3 cycles of treatment. This will therefore shorten the treatment from 10 weeks to 6 weeks, thus reducing the side effects. conditions: Testicular Neoplasms studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 36 type: ACTUAL name: Pegfilgrastim name: Dactinomycin name: Methotrexate name: Etoposide name: Cisplatin name: Epirubicin measure: Response rate to GAMEC-S or GAMEC-A measure: Relapse-free survival measure: Overall survival sex: MALE minimumAge: 16 Years maximumAge: 35 Years stdAges: CHILD stdAges: ADULT facility: Barts and the London NHS Trust city: London zip: EC1A 7BE country: United Kingdom lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06309719 id: 339479 briefTitle: Hyaluronic Acid and Polynucleotides for Supra-bony Defects overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-09 date: 2025-11 date: 2024-03-13 date: 2024-03-13 name: Queen Mary University of London class: OTHER name: Geistlich Pharma AG briefSummary: The goal of this pilot study is to describe the early wound healing molecular events and the vascularization pattern associated with the treatment of supra-bony defects with access flap alone or in association with a combined formulation of hyaluronic acid and polydeoxyribonucleotides gel. conditions: Periodontal Diseases conditions: Wound Heal conditions: Periodontal Inflammation conditions: Periodontal Pocket conditions: Periodontal Attachment Loss studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: Periodontal Access Flap (AF) + Combined Formulation of Hyaluronic acid and Polydeoxyribonucleotides (PNHA) name: Periodontal Access Flap (AF) measure: Early wound healing molecular events through GCF measure: Early gingival tissue vascularization pattern when supra-bony defects are treated with AF, in association or not with PNHA measure: Periodontal parameters and periodontal inflamed surface area (PISA) on the teeth involved in the surgery measure: Probing pocket depth (PPD) measure: Gingival recession (REC) measure: Clinical attachment level (CAL) measure: Suppuration measure: Gingival phenotype measure: Keratinized tissue (KT) measure: Full mouth plaque score (FMPS) measure: Full mouth bleeding score (FMBS) measure: Early Healing Index (EHI) measure: Gingival morphometric changes measure: Oral impact on daily performance (OIDP) measure: Dentine/root sensitivity measure: Food impaction measure: Patient perception about therapy measure: Global ratings of Periodontal Health and Quality of Life sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Barts Health NHS Trust Dental Hospital city: London zip: E1 1BB country: United Kingdom name: Vandana Luthra role: CONTACT phone: +44(0)207 882 6348 email: BHNT.Clinicaloralresearchcentre@nhs.net name: Elena Calciolari, DDS, MS, PhD role: CONTACT email: e.calciolari@qmul.ac.uk lat: 51.50853 lon: -0.12574 facility: Centre for Oral Clinical Research (COCR) city: London zip: E1 2AD country: United Kingdom name: Vandana Luthra role: CONTACT phone: +44(0)207 882 6348 email: BHNT.Clinicaloralresearchcentre@nhs.net name: Elena Calciolari, DDS, MS, PhD role: CONTACT email: e.calciolari@qmul.ac.uk lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06309706 id: JXHU briefTitle: A Retrospective Cone Beam Computed Tomography Study of The Lateral Wall Bony Window overallStatus: COMPLETED date: 2019-09-01 date: 2020-01-01 date: 2020-12-31 date: 2024-03-13 date: 2024-03-13 name: The Dental Hospital of Zhejiang University School of Medicine class: OTHER briefSummary: Three experienced observers were asked to screen all the CBCT images from the Stomatology Hospital,Zhejiang University School of Medicine, between September 1, 2019 and December 31, 2019, and counted 1000 maxillary sinus CBCT images that met the criteria. Later, 1000 CBCT images were further measured and analyzed, and indicators such as maxillary sinus buccal wall thickness, morphology, whether there is blood vessel or not, whether there is bone septa or not were counted. The variation rules and related factors were summarized by SPSS analysis. conditions: Lateral Wall Thickness studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 1000 type: ACTUAL name: No intervention measure: Lateral wall thickness sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine city: Hangzhou state: Zhejiang zip: 310000 country: China lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06309693 id: IRB-300011310 briefTitle: Postoperative Pain Management Following Robotic Assisted Sacrocolpopexy overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-10 date: 2025-10 date: 2024-03-13 date: 2024-04-05 name: University of Alabama at Birmingham class: OTHER briefSummary: In the effort to reduce postoperative opioid use, there has been increasing interest in developing multimodal pain regimens to better manage postoperative pain while minimizing opioid use and their subsequent side effects that can be detrimental to the healing process. Standard of care approaches to better manage postoperative pain include the Enhanced Recovery After Surgery (ERAS) protocol and the use of peripheral and truncal nerve blocks. Truncal nerve blocks are widely used as an additional modality to provide longer lasting postoperative analgesia and have been adopted as part of the standard of care. The goal of this clinical trial is to compare the effects of ERAS alone versus the quadratus lumborum (QL) nerve block on the postoperative pain experience for women with pelvic organ prolapse undergoing robotic assisted sacrocolpopexy. Subjects will be randomized to the ERAS protocol or the QL block. The main questions the study aims to answer are: 1) does the QL block decrease patient reported pain scores postoperatively; and 2) does the QL block decrease the amount of opioid pain medications in the immediate postoperative period? The primary outcome measure will be median patient reported pain score in the post-anesthesia care unit (PACU) following surgery. conditions: Pelvic Organ Prolapse conditions: Post Operative Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The study will be a randomized control trial in which patients undergoing robotic-assisted sacrocolpopexy with concurrent robotic assisted hysterectomy or robotic assisted sacrocolpopexy after previous hysterectomy will be randomized to one of two standard of care approaches for postoperative pain management: the enhanced recovery after surgery (ERAS) protocol and the quadratus lumborum truncal nerve block. Subjects will undergo one of two standard of care approaches to postoperative pain management and be asked about their pain postoperatively. primaryPurpose: TREATMENT masking: NONE count: 70 type: ESTIMATED name: Quadratus Lumborum (QL) Block name: Enhanced Recovery After Surgical (ERAS) Protocol measure: Median postoperative patient reported pain score in post-anesthesia recovery unit (PACU) measure: Maximum postoperative patient reported pain score in PACU measure: Total oral morphine equivalents (OME) required in PACU Total oral morphine equivalents (OME) required in post-anesthesia recovery unit measure: Rates of postoperative nausea and vomiting (PONV) in PACU measure: Rates of overnight admission measure: Total time spent in PACU measure: Rates of initial active voiding trial failures sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06309680 id: 280992 briefTitle: Accuracy of Metagenomic Blood Sampling to Identify Pathogen in Infective Endocarditis Patients acronym: AMetIP overallStatus: RECRUITING date: 2023-04-24 date: 2025-07-31 date: 2025-07-31 date: 2024-03-13 date: 2024-03-13 name: Queen Mary University of London class: OTHER name: Barts & The London NHS Trust name: Quadram Institute Bioscience briefSummary: Infective Endocarditis is an infection, usually a bacterium, which attacks the heart and can cause valves to leak and produces a bacterial mass which can break off from the valves and block the blood supply to important organs.
Accurate antibiotic regimes require detection of the causative organism and its sensitivities to each antibiotic. Antibiotic choice is then based on effectiveness, toxicity, ease of use and national guidelines. The current best technique for identifying bacteria is blood culture where organisms are identified by growing them from blood samples. However, this takes up to 5 days from sampling, resulting in delays to the correct diagnosis. Until this time, treatment requires the use of generic, more toxic antibiotic regimes.
New techniques are emerging to identify causative organisms from blood. Metagenomics allows the sequencing of bacterial DNA allowing precise identification of the infecting organism. conditions: Infective Endocarditis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED measure: diagnostic accuracy of CMg in blood measure: to evaluate the results of Nanopore CMg in identifying the causative organism in patients with BCNIE measure: 1. Optimal timing of blood sampling measure: 3. Metagenomic Techniques sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: St Bartholomew's Hospital. West Smithfield status: RECRUITING city: London zip: EC1A 7BE country: United Kingdom name: Innocent M Bvekerwa role: CONTACT phone: 07852209005 email: i.bvekerwa@nhs.net name: Simon Woldman role: CONTACT email: simon.woldman@nhs.net lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06309667 id: SL-MG12-P1 briefTitle: A Study to Assess Safety, Pharmacokinetics and Pharmacodynamics of PG-102(MG12) in Healthy Volunteers overallStatus: RECRUITING date: 2023-10-17 date: 2024-06-26 date: 2024-06-26 date: 2024-03-13 date: 2024-03-13 name: ProGen. Co., Ltd. class: OTHER briefSummary: This is a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled, combined single (Part A) multiple (Part B) ascending dose, phase 1 study to investigate the safety, tolerability and pharmacokinetic and pharmacodynamics following subcutaneous injections of PG-102(MG12) in healthy adult participants.